Icatibant Glenmark

Icatibant, the active ingredient in Icatibant Glenmark, is a bradykinin B2 receptor antagonist presented as a solution for injection for subcutaneous use. It treats acute attacks of hereditary angioedema in patients with confirmed diagnosis and is formulated for rapid administration to quickly reduce swelling and pain associated with HAE episodes.

GNH USA supplies Icatibant Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to manage hereditary angioedema by blocking the bradykinin pathway.

Hereditary angioedema type I: Rapid reduction of swelling during acute attacks. Hereditary angioedema type II: Rapid reduction of swelling during acute attacks. Hereditary angioedema with normal C1‑inhibitor: Provides symptom relief in approved regions.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain - Redness or erythema at the injection site - Local swelling or induration - Nausea - Headache - Dizziness

Serious or Rare Side Effects: - Anaphylactic reaction - Severe angioedema unrelated to HAE - Hypotension - Thrombocytopenia - Acute hypersensitivity reactions

When prescribing Icatibant, clinicians should consider several safety aspects.

Pregnancy: Safety not established; use only if benefit outweighs risk. Breastfeeding: Unknown safety; evaluate potential risks. Renal impairment: Use with caution; monitor renal function. Concomitant ACE inhibitors: Increased risk of angioedema; monitor closely. History of hypersensitivity: Contraindicated in patients with known allergy to icatibant. Store at 2-8°C: Keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medications that affect the bradykinin pathway or cardiovascular status.

Major Interactions (Avoid): - ACE inhibitors: May increase risk of angioedema. - Other bradykinin B2 receptor antagonists: Additive effect, avoid concurrent use. - Estrogen‑containing contraceptives: May raise HAE attack frequency; avoid if possible.

Moderate Interactions (Monitor Closely): - NSAIDs: Can exacerbate swelling; monitor patient response. - Diuretics: Potential for hypotension; observe blood pressure. - Antihistamines: May mask early signs of an allergic reaction; watch for symptoms.